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At a glance summary: 13 
Scientific Knowledge on the Subject:  14 Why people living with HIV who are on treatment remain at much greater risk of 15 pneumococcal disease remains unclear.   16 
What This Study Adds to the Field: 17 This study finds that, despite antiretroviral therapy there is persistent low-level viral 18 replication in the lung. Alveolar macrophages from people living with HIV-1 19 demonstrate a defect in pneumococcal killing, which is caused by the HIV-1 glycoprotein 20 gp120. This results in reduced susceptibility to macrophage apoptosis, a necessary 21 component for bacterial killing. 22  23 This article has an online data supplement, which contains supplemental figures (E1-3) 24 and a detailed description of all materials and methods and is accessible from 25 this issue's table of content online at www.atsjournals.org 26 
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Structured Abstract 1  2 
Rationale 3 People living with HIV (PLWH) are at significantly increased risk of invasive 4 pneumococcal disease, despite long-term antiretroviral therapy (ART). The 5 mechanism explaining this observation remains undefined.  6 
Objectives 7 We hypothesized apoptosis-associated microbicidal mechanisms, required to 8 clear intracellular pneumococci that survive initial phagolysosomal killing, are 9 perturbed.   10 
Methods 11 Alveolar macrophages (AM) were obtained by bronchoalveolar lavage (BAL) 12 from healthy donors or HIV-1-seropositive donors on long-term ART with 13 undetectable plasma viral load.  Monocyte-derived macrophages (MDM) were 14 obtained from healthy donors and infected with HIV-1BaL or treated with gp120. 15 Macrophages were challenged with opsonized serotype 2 Streptococcus 16 
pneumoniae and assessed for apoptosis, bactericidal activity, protein expression 17 and mitochondrial reactive oxygen species (mROS). AM phenotyping, ultra-18 sensitive HIV-1 RNA quantification and gp120 measurement were also 19 performed in BAL.  20 
Measurements and Main Results 21 HIV-1BaL infection impaired apoptosis, induction of mROS and pneumococcal 22 killing by MDM. Apoptosis-associated pneumococcal killing was also reduced in 23 AM from ART treated HIV-1-seropositive donors. BAL fluid from these 24 individuals demonstrated persistent lung CD8+ T-cell lymphocytosis, and gp120 25 or HIV-1 RNA was also detected. Despite this, transcriptional activity in AM 26 
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freshly isolated from PLWH was broadly similar to healthy volunteers.  Instead, 1 gp120 phenocopied the defect in pneumococcal killing in healthy MDM through 2 post-translational modification of Mcl-1, preventing apoptosis induction, caspase 3 activation and increased mROS generation. Moreover gp120 also inhibited mROS 4 dependent pneumococcal killing in MDM. 5 
Conclusions. 6 Despite ART, HIV-1, via gp120, drives persisting innate immune defects in AM 7 microbicidal mechanisms, enhancing susceptibility to pneumococcal disease. 8  9 
Abstract Word Count 241 10 
Introduction 11 HIV-1-seropositive individuals have a significantly increased risk of 12 pneumococcal disease that persists despite antiretroviral therapy (ART), even 13 after CD4+ T-cell reconstitution (1, 2). Alveolar macrophages (AM) are essential 14 for pneumococcal clearance from the lung (3) yet evidence of modulation of AM 15 immune competence against pneumococci by HIV-1 has proven elusive; opsonic 16 phagocytosis of pneumococci is preserved during HIV-1 infection (4) and while 17 defective phagolysosomal killing is reported for some pathogens it has not been 18 demonstrated for pneumococci (5).  19 The capacity of healthy human tissue macrophages to destroy extracellular 20 bacteria through internalization and phagolysosomal killing is finite (6) and AM 21 need to engage a second, delayed microbicidal strategy involving apoptosis-22 associated killing to eliminate residual viable intracellular pneumococci, which 23 involves combinations of reactive oxygen species (ROS) and nitric oxide (NO) (3, 24 7-9). The apoptotic program is regulated by the anti-apoptotic Bcl-2 protein Mcl-25 
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1 and induction of a mitochondrial apoptosis pathway (10). Apoptosis-1 associated killing enhances clearance of pneumococci, limits tissue invasion and 2 downregulates the inflammatory response in the lung (10, 11). Importantly, HIV-3 1 is associated with an anti-apoptotic gene expression profile in monocytes in 4 
vivo and promotes macrophage resistance to apoptosis, which contributes to 5 these cells constituting a viral reservoir for HIV-1 (12-15).  6 We addressed whether HIV-1 prevents engagement of the apoptotic program 7 required for pneumococcal killing. Here we report a selective deficit in delayed, 8 apoptosis-associated pneumococcal killing in AM from ART-treated HIV-1-9 seropositive volunteers. We document evidence of low level viral replication and 10 gp120 detection in the lung despite long-term suppressive ART and confirm that 11 HIV-1 envelope glycoprotein gp120 is sufficient to inhibit macrophage killing of 12 pneumococci in human monocyte-derived macrophage (MDM), through altered 13 post-translational regulation of Mcl-1 and failure to induce mitochondrial ROS 14 (mROS) generation.  15 Some of the results of these studies have been previously reported in the form of 16 an abstract and doctoral thesis (16, 17).17 
Materials and Methods   18 Additional detail on the method for making these measurements is provided in 19 an online data supplement. 20 
Bacteria, Virus and Infections 21 Opsonized, type 2 S. pneumoniae (D39 strain, NCTC7466) were used for infection 22 of macrophages at a multiplicity of infection of 10 unless otherwise stated, as 23 described (10). In some infections autologous peripheral blood lymphocytes 24 (PBL), or HIV-1LAI/IIIB envelope glycoprotein gp120 (NIBSC, UK) at 10-100 ng/mL 25 
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were added to MDM. HIV-1BaL (NIH AIDS Reagent Program,) was propagated in 1 PBL, then MDM and purified before cell inoculation. Infection rates were 2 measured by intracellular p24 staining as described (18).  3 
Volunteers 4 Healthy, never smoker, hepatitis B and C virus negative, HIV-1-seropositive 5 patients either established on ART or ART naïve (used as comparator for BAL 6 and virology studies), were recruited from the HIV clinic of STH for 7 bronchoscopy along with matched HIV-seronegative volunteers, described in 8 Table 1. 9 
Cell isolation and culture  10 Peripheral blood mononuclear cells (PBMC) were isolated from whole blood of 11 healthy donors and differentiated to MDM(10). Non-adherent PBMC were 12 enriched for CD8+ T-lymphocytes by negative selection and >95% purity 13 confirmed by flowcytometry. CD8+ T-lymphocytes were added 1:1 to MDM. Cells 14 were isolated from bronchoalveolar lavage (BAL) fluid as described (4).  15 
Western blot 16 Whole cell extracts were isolated using SDS-lysis buffer and separated by SDS gel 17 electrophoresis.  18 
Flow Cytometry 19 Cell surface marker expression was measured by flow cytometry with 20 fluorophore conjugated antibodies or isotype controls. MDM mROS was 21 measured using MitoSOX-Red (Invitrogen), and loss of Δψm with JC-1 (Molecular 22 probes).  23 
Microscopy 24 
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Nuclear fragmentation and condensation indicative of apoptosis were detected 1 
using 4′6′-diamidino-2-phenylindole (DAPI)(10). BAL cells were identified on 2 stained cytospins.  3 
Caspase activation 4 Cellular caspase activity was measured using Caspase-Glo 3/7 (Promega) 5 according to the manufacturer’s instructions. Luminescence was measured on a 6 Varioskan Flash microplate analyzer (Thermo Scientific). 7 
Quantification of gp120  8 BAL supernatants were concentrated using 50k Amicon Ultra-filters (Merck 9 Millipore) and gp120 quantified with human monoclonal anti-gp120 antibodies 10 (14E, 17B and EH21), using recombinant gp120 (HIV-1LAI/IIIB) for standards, by 11 ELISA, as described (19).  12 
Metabolic measurements 13 Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were 14 measured using the XF24 extracellular flux analyser (Seahorse, Bioscience) as 15 described (20).  16 
RT-PCR Array 17 AM gene expression was measured after 48 h with a custom made RT2 Profiler 18 PCR Array (SABiosciences) using QPCR.  19 
Ultra-sensitive detection of HIV-1 RNA in BAL 20 BAL HIV-1 RNA was quantified using a modified version of the Abbott Real-Time 21 HIV-1 assay (Maidenhead, UK), following ultracentrifugation similarly to 22 methods in plasma samples (21). After confirming no inhibition, sensitivity was 23 determined at 1-2 copies per mL by spiking acellular HIV-negative BAL with 24 World Health Organization 3rd International HIV-1 RNA Standard (NIBSC, UK). 25 
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Statistics 1 Results are recorded as mean and SEM unless stated. Sample sizes were 2 informed by standard errors obtained from similar assays in prior publications 3 (10, 20). Analysis was performed with tests, as outlined in the figure legends, 4 using Prism 6.0 software (GraphPad Inc.) and significance defined as p<0.05. 5 Decisions on use of parametric or non-parametric tests were informed by the 6 distribution of the data.  7  8 
 9 
Results  10 
HIV-1 inhibits delayed pneumococcal killing by macrophages  11 To examine whether HIV-1 influences macrophage killing of pneumococci we 12 infected MDM with HIV-1BaL, an M-tropic stain of HIV-1 (18) or sham virus 13 (Figure 1A) and then, after adjusting for cell numbers, challenged MDM with 14 pneumococci. The numbers of viable intracellular bacteria in MDM 4 h post 15 bacterial challenge, which are the net result of opsonic phagocytosis and 16 phagolysosomal killing (4), were unaltered by HIV-1BaL (Figure 1B).  By contrast, 17 20 h after pneumococcal challenge the intracellular bacterial load was higher in 18 HIV-1BaL MDM (Figure 1C). When we examined engagement of the MDM 19 apoptotic programme we found caspase 3/7 activation, development of 20 apoptotic nuclei and loss of cell numbers following pneumococcal challenge 21 were significantly reduced by HIV-1BaL compared to sham infection (Figure 1D-22 F). Mcl-1 was down-regulated in sham virus exposed MDM but levels were 23 preserved in HIV-1BaL MDM (Figure 1G-H). Despite comparable mitochondrial 24 density HIV-1BaL MDM had elevated production of mROS after mock-infection 25 
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but, unlike sham virus exposed MDM, failed to upregulate mROS after 1 pneumococcal challenge (Figure 1I-J). Overall these findings support a specific 2 deficit in the delayed apoptosis-associated phase of pneumococcal killing in HIV-3 1BaL MDM.  4 
 5 
Impaired apoptosis-associated pneumococcal killing in alveolar 6 
macrophages from HIV-1-seropositive individuals treated with ART. 7 
We next investigated whether alveolar macrophages (AM) from the unique lung 8 environment of asymptomatic HIV-1-seropositive individuals established on 9 ART with undetectable plasma HIV-1 viral RNA (Table 1), would also 10 demonstrate impaired pneumococcal clearance. In line with HIV-1BaL infected 11 MDM, AM from ART treated HIV-1-seropositive donors showed a selective defect 12 in delayed pneumococcal killing at 20 h (Figure 2A-B). AM in these samples also 13 showed reductions in caspase 3/7 activation, numbers of apoptotic nuclei and 14 cell loss relative to healthy controls (Figure 2C -E). The impairment of apoptosis 15 following pneumococcal challenge was not related to use of protease inhibitors 16 or non-nucleoside reverse transcriptase inhibitors as the third ART agent 17 (Figure 2F).  When we investigated the relationship between the number of HIV-18 1BaL infected MDM and apoptosis induction following pneumococcal challenge 19 we found no correlation (Figure 2G).   20 
 21 
Activation status of AM from HIV-1-seropositive individuals treated with 22 
ART is similar to healthy volunteers. 23 
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We next investigated if steady state expression of representative genes 1 associated with apoptosis and polarization was altered in AM from our donor 2 groups. Using quantitative PCR arrays we found that while there was an overall 3 trend towards downregualtion of gene expression in AM from ART treated HIV-4 1-seropositive individuals compared with healthy controls, no consistent 5 differences in the expression of these genes was observed (supplemental Figure 6 E1).  Furthermore, representative markers of macrophage polarization states 7 CD80 (M1), CD163, CD206 and CD200r (M2) also showed no significant 8 alteration in surface expression in AM from HIV-1-seropositive individuals on 9 ART (supplemental Figure E2).  10  11 
Impaired bacterial clearance by alveolar macrophages is associated with 12 
markers of viral persistence in the lungs of HIV-1-seropositive individuals 13 
on ART. 14 As pulmonary T-lymphocytes influence macrophage-mediated responses to 15 pneumococci in the airway (22), we next sought evidence of alterations to T-16 lymphocyte numbers in the airway of the asymptomatic HIV-1-seropositive 17 individuals on ART that might link HIV indirectly to the observed AM phenotype. 18 We first analyzed the BAL cell content and included 3 ART-naive HIV-1-19 seropositive individuals. Both ART-naïve individuals and those receiving ART 20 had increased lymphocyte numbers in BAL fluid (Figure 3A). Compared to 21 healthy controls, ART-treated HIV-1-seropositive individuals also had a lower 22 percentage of CD4+ T-lymphocytes yet a higher proportion of CD8+ T-23 lymphocytes and lower CD4+:CD8+ T-lymphocyte ratio (Figure 3B-D, Table 1 and 24 supplemental Figure E2). In addition, we found that the ratio of CD4+:CD8+ T-25 
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lymphocytes in BAL correlated with the induction of AM apoptosis, following 1 pneumococcal challenge (Figure 3F). We next explored whether T-lymphocyte 2 CD38 expression, a marker of immune activation in HIV-1 that correlates with 3 viral load (23), was increased in the ART-treated HIV-1-seropositive donors.  4 However, CD8+ T-lymphocytes showed no difference in CD38 expression (Figure 5 3E). We also tested whether in vitro activated, autologous CD8+ T-cells, could 6 alter MDM engagement of apoptosis-associated killing but found no modulation 7 of MDM viability, apoptosis or intracellular bacterial survival (supplemental 8 Figure E3A-C).  9 The CD4:CD8 ratio in ART-treated HIV-1-seropositive individuals is inversely 10 related to the size of the HIV-1 reservoir in the peripheral blood (24). Therefore 11 we considered an alternative possibility that BAL CD4:CD8 ratio was a marker of 12 persistent HIV-1 replication in the lung; we detected HIV-1 p24 in AM cultures 13 from 2/2 ART-naïve and 3/10 ART-treated HIV-1-seropositive donors 14 respectively (Figure 3G). Using ultrasensitive assays HIV-1 RNA was detected at 15 79 copies/mL and 1-4 copies/mL of cell free BAL fluid supernatants from 1/1 16 ART-naïve and 2/13 (15.4%) ART-treated HIV-1-seropositive donors 17 respectively. However, the number of donors with detectable p24 or RNA were 18 too few to determine any correlation between these markers of HIV replication 19 and the BAL CD4:CD8 ratio. 20  21 
gp120 impairs bacterial killing by reducing macrophage susceptibility to 22 
apoptosis following pneumococcal challenge  23 We detected HIV-1 envelope glycoprotein (gp120) in a 10–100ng/mL range in 24 BAL fluid from five of 11 (45.5%) of the ART-treated and in one of two ART-25 
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naïve HIV-1-seropositive donors tested, and observed that those on ART with 1 detectable gp120 also had significantly lower peripheral blood CD4+ counts 2 (Figure 4A). Recombinant gp120 recapitulated the selective deficit in delayed 3 phase pneumococcal killing by MDM (Figure 4B-C) and reduced both numbers of 4 apoptotic nuclei and caspase 3/7 activation following pneumococcal challenge 5 (Figure 4D-E). gp120 was also associated with a baseline increase in mROS, 6 without altering mitochondrial density, but gp120 exposed MDM failed to 7 upregulate mROS after pneumococcal challenge (Figure 4F-G). mROS production 8 was abrogated by MitoTEMPO, a mitochondria-targeted superoxide dismutase 9 mimetic that possesses superoxide and alkyl radical scavenging properties, 10 confirming mitochondria as the source of ROS (Figure 4F). 11 When we analyzed the bioenergetic response of MDM we observed that 12 pneumococcal challenge led to an increase in baseline extracellular acidification 13 rate (ECAR) and a reduction in maximal oxygen consumption rate (OCR Max), 14 and this switch in metabolism was unaltered by gp120 (Figure 4I-L). 15 Pneumococcal challenge resulted in increased proton leak across the inner 16 mitochondrial membrane (Figure 4M). However, this response and the loss of 17 
mitochondrial inner transmembrane potential (Δψm) were diminished by gp120 18 (Figure 4H).  19 We next analysed whether abrogation of mROS upregulation, with an mROS 20 inhibitor MitoTEMPO, altered intracellular pneumococcal killing.  After 21 challenging MDM with pneumococci we observed no difference in the number of 22 viable intracellular bacteria after 4 h in the presence of gp120 or mitoTEMPO. 23 However, addition of MitoTEMPO to control MDM increased bacterial survival at 24 
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20 h to the same level seen with gp120, but had no effect on viability in gp120 1 exposed MDM at two distinct multiplicities of infection (Figure 5).  2  3 
gp120 impairs macrophage apoptosis by altering the post-translational 4 
modification of Mcl-1  5 gp120 prevented downregulation of Mcl-1 (Figure 6A-B) and reduced 6 ubiquitination of Mcl-1 after pneumococcal challenge (Figure 6C-D).  7 Ubiquitination of Mcl-1 is tightly regulated and ubiquitination is reversed by the 8 de-ubiquitinase (DUB) USP9X (25).  We detected decreased expression of USP9X 9 following pneumococcal challenge in control MDM but treatment with gp120 10 abrogated this response (Figure 6E-F).  11  12  13 
Discussion 14  15 Here we demonstrate for the first time that HIV-1 impairs pneumococcal killing 16 by macrophages. We show HIV-1 is associated with specific defects in the late 17 phase of pneumococcal killing by impairing apoptosis induction and reducing 18 caspase-dependent induction of mROS.  Critically, we find this defect in AM from 19 HIV-1-seropositive individuals established on long-term antiretroviral therapy 20 with good immune reconstitution. Furthermore, despite extended periods of 21 ART we find evidence of altered cellular immune responses, viral replication and 22 release of the HIV-1 envelope glycoprotein gp120 in the lungs. gp120 is sufficient 23 to reprise the deficit in pneumococcal killing and does so via altered post-24 translational regulation of Mcl-1, a key regulator of macrophage apoptosis.   25  26 
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AM are essential for pneumococcal clearance; they initially resist pro-apoptotic 1 stimuli while engaging phagolysosomal bacterial killing but subsequently 2 activate apoptosis, which facilitates bacterial clearance whilst minimizing 3 inflammation (3, 10). We found that HIV-1BaL impaired host-mediated MDM 4 apoptosis during pneumococcal infection and this was associated with a failure 5 to clear internalized pneumococci. Mcl-1 levels were maintained in the HIV-1BaL 6 infected MDM following pneumococcal challenge while caspase 3/7 activation 7 was reduced, indicating that the mitochondrial pathway of apoptosis, implicated 8 in bacterial killing, was impaired (3, 10). This extends prior observations 9 implicating HIV-1 in altered regulation of Bcl-2 family proteins (13, 26).  10  11 Caspase 3 activation promotes release of mROS by inhibiting the mitochondrial 12 electron transport complex I and has been identified as a requirement for the 13 increment of mROS generation that is required to mediate apoptosis-associated 14 killing of intracellular pneumococci (20, 27). The failure of HIV-1BaL infected 15 MDM to increase mROS production over baseline following pneumococcal 16 challenge resulted in pneumococcal survival, similar to recent observations in 17 AM from COPD patients (20). In contrast to the requirement for a late increment 18 in mROS to achieve optimal intracellular killing, chronic baseline elevation of 19 mROS, following HIV-1 or gp120 exposure, does not seem to enhance 20 intracellular bacterial killing. Consistent with this an inhibitor of mROS had no 21 impact on early intracellular bacterial viability at 4 h. COPD AM also show 22 chronic baseline elevation of intracellular mROS but no enhancement of early 23 intracellular bacterial killing (20). To play a role in intracellular killing mROS 24 needs to be generated in proximity to bacteria in phagolysosomes (20, 28) and 25 
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be produced at levels above baseline following caspase 3 activation to 1 overwhelm anti-oxidant systems (20).  In COPD there is not only reduced 2 caspase 3/7 activation but also an altered balance between mROS generation 3 and superoxide dismutase (SOD) 2 expression, which suggests increased ability 4 to neutralize baseline mROS. Recent observations show gp120 also upregulates 5 SOD in microglia (29). It is noteworthy that, like COPD, HIV-1 has been 6 associated with chronic increases in oxidative stress in mononuclear phagocytes, 7 despite antiretroviral therapy (30, 31), and adaptions to this in both conditions 8 are predicted to impair the capacity to generate a microbicidal response. 9  10 HIV-1 infects and replicates in macrophages and, while establishing a long-lived 11 cellular viral reservoir (15), induces resistance to apoptosis (12, 26). Our finding 12 that HIV-1 infection is linked to intrinsic impairments in macrophage apoptotic 13 responses is supported by previous studies with Mycobacterium tuberculosis 14 (32), but to the best of our knowledge ours is the first report of impaired killing 15 of pneumococci or any other acute extracellular bacterial infection. Crucially, we 16 have confirmed our findings in clinically relevant AM from aviraemic HIV-1-17 seropositive individuals.   18 Untreated, HIV leads to AIDS and increased rates of opportunistic infection, 19 including bacterial pneumonia and IPD (33).  Although ART inhibits viral 20 replication, reconstitutes cell mediated immunity and dramatically reduces 21 opportunistic infection, IPD remains 35 fold and bacterial pneumonia 20 fold 22 more common in HIV-1-seropositive individuals in the era of ART (2, 34-36). Our 23 findings suggest that persisting defects in the macrophage microbicidal response 24 contribute to this risk of pneumococcal disease.  25 
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 1 We hypothesized that the observed reductions in delayed bacterial killing were 2 due to indirect effects of HIV-1; only a minority of AM in ART-naïve individuals 3 are infected with HIV-1 (37) and, furthermore, within 24 weeks of ART initiation 4 there are large reductions in both BAL fluid RNA and cell-associated HIV-1 5 nucleic acid (38). Our volunteers had received a median of 75 months ART and 6 had no HIV-1 RNA detectable in peripheral blood by standard assays. Our in vitro 7 MDM model allows manipulation of the percentage of MDM that are positive in a 8 culture (18) and we saw no association between the rate of direct MDM HIV-1 9 infection and apoptosis. Macrophage effector functions are influenced by their 10 activation status (39) and AM from ART-naïve HIV-1-seropositive individuals 11 show classical (M1) activation (37, 40, 41). However, when we measured the 12 activation status and transcriptome of AM from our virally suppressed HIV-1 13 donors we found no difference from healthy controls. While the plasticity of 14 macrophages makes it conceivable that differences in activation and gene 15 transcription could be lost during AM isolation and culture (40, 42), we conclude 16 that once established on long-term ART, HIV-1 seropositive have no persisting 17 changes in transcriptional pathways regulating AM activation. 18  19 T-lymphocytes influence early macrophage-mediated innate immune responses 20 to pneumococci in the airway (22). Consistent with prior reports (38) ART-naïve 21 individuals had increased lymphocyte numbers in BAL fluid but, surprisingly, we 22 also observed persistent lymphocytosis in the BAL of individuals receiving ART. 23 Furthermore, they had a lower CD4:CD8 T-lymphocyte ratio that correlated with 24 altered AM apoptosis. This is a noteworthy finding since low CD4:CD8 ratios in 25 
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the peripheral blood of ART-treated HIV-1-seropositive individuals are linked to 1 non-AIDS morbidity, immune activation, inflammation and heightened CD8+ T 2 cell activation (43). While there may be a role for specific subsets of CD8+ T-3 lymphocytes influencing AM behavior in the lung, we found no elevated CD38 4 expression on BAL T-lymphocytes and no effect on apoptosis or bacterial killing 5 when we explored the influence of activated CD8+ T-lymphocytes on MDM 6 responses to pneumococci in vitro. Thus these suggest that global changes in 7 CD8+ T-lymphocytes are a biomarker of intermittent low-level viral replication 8 but do not directly mediate the inhibition of macrophage apoptosis-associated 9 bacterial killing. 10  11 We also found evidence for ongoing viral replication in the lungs of some ART-12 treated individuals by either directly detecting viral RNA, p24 in AM or gp120 in 13 BAL samples. These results add to the observation that potentially replication-14 competent virus persists in lung AM despite long-term ART (44) and extend 15 reports of detectable gp120 in histological lung specimens of virally suppressed 16 individuals (45).  This study measured a snapshot of viral RNA and gp120 and 17 was not powered to detect a relationship between these markers of viral 18 replication and the BAL lymphocyte count or CD4:CD8 ratio. However, the 19 persistence of altered BAL CD4: CD8 T-cell ratios are more likely to be a function 20 of cumulative periods of episodic HIV replication in the lung with normalization 21 of this ratio requiring sustained suppression of viral replication, as described in 22 the peripheral blood (24).   23  24 
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We have been able to demonstrate that recombinant gp120 is sufficient to 1 recapitulate the impairment in delayed phase pneumococcal killing related to 2 HIV-1 infection. HIV-1 envelope (gp120) has been shown to be necessary for 3 macrophage resistance to apoptosis acutely after a single cycle of replication 4 with X4- or R5-tropic HIV-1 (13) while gp120 when disassociated from virus, is 5 sufficient to influence macrophage function and apoptosis resistance (14, 46, 6 47). Importantly, we observed this effect at concentrations of gp120 similar both 7 to those we found in the BAL and commensurate with those described in other 8 anatomical compartments in HIV-1-seropositive individuals (46).  9  10 As with HIVBaL, we observed a failure of gp120 treated MDM to down regulate 11 Mcl-1. Mcl-1 is regulated by ubiquitination and proteasomal degradation (9). 12 Consistent with the paucity of transcriptional changes involving apoptosis 13 regulators in AM from ART-treated HIV-1 donors, we found that gp120 altered 14 post-translational modification of Mcl-1 through reduced ubiquitination in 15 association with upregulation of the DUB USP9X. Thus while Mcl-1 16 transcriptional upregulation is an immediate intrinsic response to HIV-1 17 infection (13) we propose that in the context of pneumococcal challenge gp120 18 mediates the anti-apoptotic phenotype on bystander macrophages through 19 reduced ubiquitination, and the resultant loss of proteasomal degradation of 20 Mcl-1 (10).    21  22 gp120 treatment also induced basal mROS but prevented further generation of 23 mROS in response to caspase 3/7 activation following pneumococcal challenge. 24 When we interrogated the bioenergetic response of MDM we observed a switch 25 
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to glycolytic metabolism following pneumococcal challenge in keeping with a 1 greater reliance on glycolytic metabolism during innate immune responses 2 associated with classical activation in macrophages. We also observed increased 3 proton leak which is predicted to enhance mROS generation since under these 4 conditions complex I is inhibited by caspase activation (27). However, both the 5 uplift in proton leak and loss of mitochondrial inner membrane potential were 6 diminished by gp120. Taken together these results indicate that despite raised 7 baseline levels gp120 reduces caspase-induction of mROS, a critical microbicidal 8 effector (20, 27, 28). 9  10 In conclusion, our findings suggest specific defects in the late phase of 11 pneumococcal killing by AM contribute to the sustained increase in susceptibility 12 to pneumococcal disease in PLWH.  Furthermore, despite long-term ART, we find 13 evidence of viral replication resulting in release of gp120 in the lungs associated 14 with HIV-1. Through Mcl-1 mediated inhibition of apoptosis, gp120 reduces 15 caspase-dependent induction of mROS and its important microbicidal effects 16 (20). Significantly the inhibition of apoptosis was not part of a global shift in 17 transcriptional networks regulating cell viability but arose in response to 18 impairment of a critical post-translational pathway that regulates macrophage 19 viability. Since the pathway involves ubiquitination of Mcl-1, and is associated 20 with a critical Mcl-1 deubiquitinase USP9X (25), this pathway merits 21 investigation as a potential therapeutic target.   22  23  24 
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 7 
Figure legends 8 
Figure 1 HIV-1BaL infection is associated with reduced apoptosis-associated 9 
pneumococcal killing by macrophages. 10 Representative photomicrographs of human monocyte-derived macrophages 11 (MDM) challenged with HIV-1BaL or sham virus and stained for the presence of 12 p24 (blue) (A). Scale bar = 50 µm. Sham or HIV-1BaL MDM were challenged with 13 
S. pneumoniae (D39) for 4 h (B) or 20 h (C), and lysed to determine the log 14 colony forming units (CFU)/ml, n=15, *=p<0.05, paired Student’s t-test. 15 Alternatively MDM were challenged with D39 or mock infected (MI) for 16 h and 16 caspase 3/7 luminescence measured (D), n=11, *=p<0.05, paired Student’s t-test, 17 or for 20 h and the percentage of apoptotic nuclei (E) or cells per high per field 18 (hpf) estimated (F), both n=14, ***=p<0.001, *=p<0.05, 2 way ANOVA. 19 Additionally cells were challenged for 20 h then lysed and western blot 20 performed for estimation of Mcl-1 (G) and densitometry performed (H), or 21 challenged for 16 h and stained with Mitotracker to estimate mitochondrial 22 density with relative fluorescence units (RFU) (I) or with MitoSOX to estimate 23 
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fold induction of mitochondrial reactive oxygen species (mROS) vs. sham 1 infection (J), both n=5, **p=<0.01, *=p<0.05, 2 way ANOVA. 2  3 
Figure 2 People living with HIV have impaired alveolar macrophage 4 
apoptosis associated killing of pneumococci.  5 Alveolar macrophages (AM) from ART treated HIV-1+  (ART) or control donors 6 were challenged with S. pneumoniae (D39) for 4 h (A) n=8/12 or 20 h (B) 7 n=7/12 and numbers of viable intracellular bacteria determined, *=p<0.05, 8 unpaired Student’s t-test. Alternatively HIV-1-seropositive or control AM were 9 exposed to D39 or mock infected (MI) for 16 h and caspase 3/7 activity 10 measured (C), n=5/11, *=p<0.05, unpaired Student’s t-test or for 20 h and 11 nuclear features of apoptosis recorded (D) or cell numbers assessed (E) both 12 n=8/14, **=p<0.01, ***=p<0.001, 2 way ANOVA. Nuclear features of apoptosis in 13 AM were determined separately from HIV-1-seropositive donors who had used 14 non-nucleoside reverse transcriptase inhibitor (NNRTI) or protease inhibitor 15 (PI) exclusively as the third ART agent (F), n= 7/6.  HIV-1BaL or sham-virus 16 exposed monocyte-derived macrophages (MDM) were challenged D39 for 20 h 17 and apoptosis assessed by nuclear morphology. The value for the HIV-1BaL 18 apoptosis increment was subtracted from the value for the sham-virus exposed 19 MDM increment to calculate the ∆% apoptosis and plotted against the 20 percentage of p24+ positive MDM, measured by immunohistochemistry n=13 21 (G).  22  23 
Figure 3 People living with HIV have altered T-lymphocyte numbers in the 24 
lung associated with markers of viral replication.  25 
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Bronchoalveolar lavage (BAL) cells were isolated from HIV-1-seronegative 1 (control n=10) and ART-naive HIV-1-seropositive (naïve, n=3) or ART-treated 2 HIV-1-seropositive (ART n=14) donors and the percentage lymphocytes 3 determined from cytospins (A). Flow cytometry was used to estimate the 4 percentages of CD3+CD4+ and CD3+CD8+ BAL lymphocytes for controls (n=6) and 5 ART-treated (n=11) and the mean ratio of CD4+:CD8+ lymphocytes calculated for 6 each (3.79 ± 0.76 and 1.16 ± 0.15 respectively)(B-D and supplemental figure 2), 7 **=p<0.01, Mann Whitney test, or the expression of CD38 on CD3+CD8+  BAL 8 lymphocytes (controls n=5, ART n= 9)(E). The ratio correlated to levels of AM 9 apoptosis (n=15)(F), ** p<0.01, Pearson. AM from ART donors were stained with 10 anti-p24 and XGal conjugated secondary antibodies (G). The photomicrograph 11 demonstrates blue p24 positive AM and is representative of photomicrographs 12 from 3 donors, scale bar = 50 µm.  13 
 14 
Figure 4 gp120 modifies mitochondrial ROS production following 15 
pneumococcal challenge and impairs bacterial killing. 16 gp120 was measured by sandwich ELISA in the bronchoalveolar lavage (BAL) 17 fluid from 11 ART treated HIV-1 seropositive donors and peripheral blood CD4+ 18 counts were compared in HIV-1-seropositive donors with and without 19 detectable gp120 in the BAL (A), n=5/6, **=p<0.01, Mann Whitney test. 20 Monocyte-derived macrophages (MDM) were treated with 10ng/mL gp120 or 21 media then challenged with S. pneumoniae (D39) and viable intracellular 22 bacteria (cfu) were estimated after 4 h (B) and 20 h (C), n=15, *=p<0.05, paired 23 Student’s t-test, or nuclear features of apoptosis estimated after 20 h incubation 24 and compared with mock infection (MI)(D), n=8, *=p<0.05, 2 way ANOVA. 25 
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Alternatively MDM were treated with 100ng/mL gp120 or media then 1 challenged with D39 or mock infected (MI) for 16 h before quantifying caspase 2 3/7 activity (E), n=7,  *=p<0.05, paired Student’s t-test, mitochondrial reactive 3 oxygen species (mROS), in the presence or absence of MitoTEMPO (mT) (F), n=4-4 8, **=p< 0.01 2 way ANOVA,  #=p<0.005 Mann Whitney test (vs. no mT), 5 mitochondrial density (G), n=4, loss of mitochondrial inner transmembrane 6 potential (Δψm), (H), n=3, *=p<0.05, **=p< 0.01, 2 way ANOVA or using a 7 Seahorse XF24 extracellular flux analyzer to measure oxygen consumption rate 8 (OCR) (I) and extracellular acidification rate (ECAR) (K) and calculate maximum 9 OCR (J), basal ECAR (L) and proton leak (M), all n=6, *=p<0.05, **=p< 0.01, 10 ***=p<0.001, ****=p<0.0001, 2 way ANOVA. Oligo (oligomycin A), Rot 11 (rotenone), AntA (antimycin A).  12  13 
Figure 5 mROS dependent intracellular pneumococcal killing in 14 
macrophages is inhibited by gp120 treatment. 15 Monocyte-derived macrophages (MDM) were treated with 100ng/mL gp120 or 16 media in the presence of vehicle or MitoTEMPO (mT) then challenged with S. 17 
pneumoniae (D39) at multiplicity of infection 10 (A) or 100 (B) and viable 18 intracellular bacteria (cfu) were estimated after 4 h and 20 h, n=5 (A), or 20 h n= 19 6 (B) ****=p<0.0001, *=p<0.05 vs 20 h control, 1 way ANOVA. 20 
 21 
Figure 6 gp120 modulates post-translational regulation of Mcl-1 in MDM  22 
following pneumococcal challenge. 23 Monocyte-derived macrophages (MDM) were treated with 100ng/mL gp120 or 24 media then challenged with S. pneumoniae (D39) or mock infected (MI) before 25 
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lysing cells at 20 h and performing Western blots to estimate Mcl-1 (A-B) or 1 lysing cells at 16 h and performing ubiquitin pull-down followed by western 2 blotting for Mcl-1 or total ubiquitinated proteins (C-D). Alternatively cells were 3 lysed at 20 h and blotted for USP9X (E-F). In each case a representative western 4 blot is depicted with the result of densitometry performed on three separate 5 western blots with data shown as fold change in band density compared with 6 mock infected control MDM after adjustment for any fold change in loading 7 control, *=p<0.05, **=p<0.01, 2 way ANOVA. 8  9 
 10 
11 
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Tables  1 
Table 1 Healthy and HIV-1 seropositive alveolar macrophage donors 2  3  HIV-1 on ART HIV-1 ART-NAÏVE CONTROL   n or mean ± SEM Age (years) 42.4 ± 2.4 41.7 ± 5.3 40.8 ± 2.7 Sex      Male  8 3 8   Female 6 0 4 Ethnicity     White  9 3 9  Black African 4 0 3  other  1 0 0     Nadir CD4 (cells/mm3) 213 ± 26 587 ± 105 n/a CD4 (cells/mm3) 643 ± 51 672 ± 176 n/a CD4:CD8 0.83 ± 0.07 0.66 ± 0.003 n/a plasma HIV-1 RNA    (log10 copies/mL)                   undetectable 4.43 ± 3.84 n/a 3rd ART agent     PI 6 n/a n/a  NNRTI 7 n/a n/a  Mixed / other regimen 1 n/a n/a  Duration (months)   75 (43-108)*   
* median with interquartile range, PI = Protease Inhibitor, NNRTI = Non-4 Nucleoside Reverse Transcriptase Inhibitor5 6 
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